fucoidan (BAX 513)
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 13, 2024
Anti-Inflammatory, Antidiabetic, and Antioxidant Properties of Extracts Prepared from Pinot Noir Grape Marc, Free and Incorporated in Porous Silica-Based Supports.
(PubMed, Molecules)
- "The anti-inflammatory potential against COX and LOX enzymes of selected samples was evaluated and compared with that of Indomethacin and Zileuton, respectively. The best anti-inflammatory activity was observed when PN extract was loaded on MCM-NH2-Fuc support."
Journal • Infectious Disease • Inflammation
April 27, 2024
Treatment of Cachexia in Gastric Cancer: Exploring the Use of Anti-Inflammatory Natural Products and Their Derivatives.
(PubMed, Nutrients)
- "(3) Natural anti-inflammatory products represent a potential adjunctive therapy for gastric cancer cachexia. Further research, particularly well-designed clinical trials, is needed to elucidate their optimal role, dosing and safety profiles in the management of gastric cancer cachexia."
Journal • Review • Cachexia • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
February 24, 2024
The Antioxidant and Anti-Inflammatory Properties of Wild Bilberry Fruit Extracts Embedded in Mesoporous Silica-Type Supports: A Stability Study.
(PubMed, Antioxidants (Basel))
- "For the extract encapsulated in an MCM-SH support, a lower IC50 value (0.69 μg/mL) towards COX-2 was obtained, comparable with that of Indomethacin (0.6 μg/mL). Also, this sample showed a higher selectivity index (2.71) for COX-2 than the reference anti-inflammatory drug (0.98). The developed formulations with antioxidant and anti-inflammatory properties could be further used in nutraceuticals."
Journal
December 03, 2022
[PREPRINT] Unveiling the anti-glioma potential of a marine derivative, Fucoidan: its synergistic cytotoxicity with Temozolomide-an in vitro and in silico experimental study
(bioRxiv)
- "The dual-drug combination significantly reduced the cell viability and migration of glioma cells in a synergistic dose-dependent manner. At the molecular level, the dual-drug combination significantly down-regulated inflammatory genes with a concomitant upregulation of pro-apoptotic marker. In consensus with our in vitro findings, molecular docking and simulation studies revealed that the anti-tumor ligands: Temozolomide, Fucoidan with 5-(3-Methy1-trizeno)-imidazole-4-carboxamide (MTIC), and 4-amino-5-imidazole-carboxamide (AIC) had the potency to bind to the inflammatory proteins at their active sites, mediated by H-bonds and other non-covalent interactions."
Preclinical • Preprint • Glioma • Oncology
June 18, 2012
Mode of action for anticoagulant activities of non-anticoagulant sulphated polysaccharides
(WFH 2012)
- U.p. fucoidan increased clotting time by 50% at 4lg/mL, which represents a two-fold higher anticoagulant effect than the other fucoidans; All fucoidans clearly increased HCII-mediated thrombin inhibition at concentrations below 1 lg/mL
MOA • Hemophilia
June 30, 2015
Determination of the active transport of fucoidan derived from Okinawa Mozuku across the human intestinal Caco-2 cells as assessed by size-exclusion chromatography.
(PubMed)
- "We firstly report that the active transport occurs for such a high molecular-weight sulphated-polyfucose of fucoidan in vitro using Caco-2 cells."
Journal • Biosimilar
1 to 6
Of
6
Go to page
1